Novel melanoma therapy

Table 2 Recent checkpoint inhibitor study results in melanoma

Study	Phase of study	Prior Tx	Agent	ORR (%)	PFS	OS
[25]	I	Yes/no	Pembrolizumab	31–51	>7 months	NA
[5]	I	Yes	Pembrolizumab	26	37–45 % at 6 months	58–63 % at 1 year
[26]	II	Yes	Pembrolizumab	21–25	34–38 % at 6 months	NA
[26]	II	Yes	Chemotherapy	4	16 % at 6 months	NA
[27] [28]	I/II	Yes/no	Pembrolizumab	33	35 % at 1 year	23 months 40 % at 3 years
[29] [30]	III	No	Pembrolizumab	32.9–33.7	46.4-47.3 % at 6 months	55 % at 2 years
[29] [30]	III	No	Ipilimumab	11.9	26.5 % at 6 months	43 % at 2 years
[6]	I	Yes	Nivolumab	31	27 % at 2 years	16.8 months 43 % at 2 years
[32]	III	No	Nivolumab	40.0	5.1 months	72.9 % at 1 year
[32]	III	No	DTIC	13.9	2.2 months	42.1 % at 1 year
[33]	III	Yes	Nivolumab	31.7	48 % at 6 months	NA
[33]	III	Yes	Chemotherapy	10.6	34 % at 6 months	NA

Prior Tx patients with prior treatment for metastatic melanoma included. Yes/No indicates a mixed population of treatment naïve and pre-treated patients

ISSN: 2162-3619